Clinical Trials Browser

Not yet recruiting × Lymphoma, T-Cell, Peripheral × Clear all

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07288814 2025-12-17

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Phase 1/2 Not yet recruiting

43 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

Phase 2 Not yet recruiting

31 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Phase 1/2 Not yet recruiting

48 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07192471 2025-09-25

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

72 enrolled

DermatologicLymphoid

Immune System Diseases, Lymphoma, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Phase 2 Not yet recruiting

30 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06385522 2025-07-08

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Phase 1 Not yet recruiting

37 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Phase 2 Not yet recruiting

35 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06963632 2025-05-09

JOYCE

Not yet recruiting

1,000 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06757387 2025-01-03

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 1/2 Not yet recruiting

45 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06712173 2024-12-02

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1 Not yet recruiting

33 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06702605 2024-11-25

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Phase 2 Not yet recruiting

50 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06548347 2024-08-12

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Phase 2/3 Not yet recruiting

606 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05900089 2023-06-12

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Phase 1 Not yet recruiting

30 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

T-START-M1

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Golidocitinib Combined With GemOx in RR PTCL

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

JOYCE

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma